Based on interim clinical trial results (NCT01968109) of BMS-986016 in a cohort of patients (68) with melanoma, an overall response rate of 11.5% and a disease control rate of 49% were achieved among patients who progressed despite prior anti-PD-1/PD-L1 therapy [89]. This evidence concerns the gene PDCD1 and melanoma.